Yun Zhong, PhD, Joins Wedbush Securities as Senior Vice President, Equity Research, Biotechnology

BusinesswireDec 3 21:30

Optimistic Buy Rating for Passage Bio Driven by Promising PBFT02 Therapy Potential and Accelerated Approval Pathway

TipRanksDec 2 20:46

Passage Bio Assumed With an Outperform at Wedbush

Yahoo FinanceNov 30 19:55

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaNov 30 05:06

Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating

MT NewswiresNov 29 22:00 · Ratings

Express News | Passage Bio Inc : Wedbush Assumes Coverage With Outperform Rating; Price Target $4 Vs $3

BreakingsNov 29 19:37